Le Lézard
Classified in: Health, Business

Brexit and the Impact to Your Global Business Operations: What Life Sciences Companies Need to Know Now Webinar, Nov. 1, 2018


FALLS CHURCH, Va., Oct. 18, 2018 /PRNewswire-PRWeb/ -- Brexit and the Impact to Your Global Business Operations:
What Life Sciences Companies Need to Know Now
**An FDAnews Webinar**
Nov. 1, 2018 ? 1:30 p.m. ? 3:00 p.m. ET
http://www.fdanews.com/brexitimpactglblbusops

When Britain exits the EU, what happens?

The EMA is moving to from London to Amsterdam in March 2019 and will lose 30 percent of its staff. The agency has already stopped accepting and publishing clinical trials data.

What about the legal uncertainty regarding contracts involving both the UK and other EU member states?

Brexit is about to happen and drug and devicemakers need to make plans before it does. Prepare to discover:

Brexit will be finalized on March 29, 2019. Manufacturers need to know how it will impact their global operations. Register today to minimize potential disruptions.

Meet the Presenter
Michael Burke, Partner, Corporate Practice, Arnall Golden Gregory

Michael Burke provides practical and actionable legal and compliance guidance that allows companies to focus on business growth. He helps companies minimize risk and maximize return across a wide range of domestic and cross-border corporate and commercial transactions and regulatory issues. Mike is a partner in the Corporate Practice and co-chairs Arnall Golden Gregory's Pharmaceuticals and Medical Devices Industry Team. Mike co-chairs the American Bar Association-United Nations Development Programme International Legal Resource Center and is the immediate past chair of the American Bar Association's Section Officer's Conference.

Who Will Benefit
Any quality or regulatory professional at a life sciences company with operations involving the European Union and the United Kingdom including:

Webinar Details:
Brexit and the Impact to Your Global Business Operations:
What Life Sciences Companies Need to Know Now
**An FDAnews Webinar**
Nov. 1, 2018 ? 1:30 p.m. ? 3:00 p.m. ET
http://www.fdanews.com/brexitimpactglblbusops

Tuition:
$287 per site

Easy Ways to Register:
Online:     http://www.fdanews.com/brexitimpactglblbusops                            
By phone: 888-838-5578 or 703-538-7600

About FDAnews:
FDAnews is the premier provider of domestic and international regulatory, legislative, and business news and information for executives in industries regulated by the US FDA and the European Medicines Agency. Pharmaceutical and medical device professionals rely on FDAnews' print and electronic newsletters, books and conferences to stay in compliance with international standards and the FDA's complex and ever-changing regulations.

 

SOURCE FDANEWS


These press releases may also interest you

at 02:32
With every successive year, the lines between medical devices and consumer electronics become increasingly blurred ? medtech companies seek to expand their reach beyond patients, and consumer electronics companies have targeted medical applications...

18 avr 2024
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The report titled "Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global...

18 avr 2024
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a...



News published on and distributed by: